Invesco
PLX icon

Invesco’s Protalix BioTherapeutics PLX Stock Holding History

Invesco’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$103K Sell
47,402
-3,161
-6% -$7.84K ﹤0.01% 3622
2025
Q4 		$91K Buy
50,563
+5,560
+12% +$11.4K ﹤0.01% 3646
2025
Q3 		$99.9K Sell
45,003
-138
-0.3% -$225 ﹤0.01% 3683
2025
Q2 		$66.8K Buy
+45,141
New +$92.3K ﹤0.01% 3699
2024
Q2 		– Sell
-25,908
Closed -$32.6K – 3950
2024
Q1 		$32.6K Sell
25,908
-976
-4% -$1.46K ﹤0.01% 3826
2023
Q4 		$47.9K Sell
26,884
-29,531
-52% -$45.9K ﹤0.01% 3753
2023
Q3 		$93.6K Buy
56,415
+34,763
+161% +$62.4K ﹤0.01% 3726
2023
Q2 		$43.3K Buy
+21,652
New +$51.6K ﹤0.01% 3825
2019
Q1 		– Sell
-3,596
Closed -$11K – 3791
2018
Q4 		$11K Sell
3,596
-133
-4% -$632 ﹤0.01% 3776
2018
Q3 		$27K Sell
3,729
-564
-13% -$2.83K ﹤0.01% 3838
2018
Q2 		$18K Buy
+4,293
New +$19.1K ﹤0.01% 3838

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Invesco's PLX Position: Q1 2026 in Review

Invesco reduced its Protalix BioTherapeutics (PLX) stake by 6.3% in Q1 2026, selling an estimated $7.84K and leaving 47,402 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #3622.

Invesco first reported a position in PLX in Q2 2018 and has held it in 11 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Invesco held 47,402 shares of Protalix BioTherapeutics worth $103K as of Q1 2026.
  • Invesco sold 3,161 Protalix BioTherapeutics shares in Q1 2026, an estimated $7.84K.
  • Protalix BioTherapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3622 holding.
  • Invesco first reported a position in Protalix BioTherapeutics in Q2 2018 and has held it in 11 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.